Kapuria Devika, Upadhyay Shubhra, Shekhar Rahul, Torrazza-Perez Euriko
Department of Gastroenterology, University of New Mexico Health Science Center, Albuquerque, NM, USA.
Department of Internal Medicine, University of New Mexico Health Science Center, Albuquerque, NM, USA.
J Clin Transl Hepatol. 2020 Dec 28;8(4):463-466. doi: 10.14218/JCTH.2020.00053. Epub 2020 Nov 11.
The novel coronavirus 2019 (COVID-19) was reported by the World Health Organization in December 2019, and since then it has progressed into a worldwide pandemic, causing significant morbidity and mortality. Gastrointestinal symptoms of COVID-19 and elevated liver chemistries are seen in up to 50% of infected patients. Recent reports have suggested a high mortality rate for COVID-19 in patients with pre-existing liver disease, having an associated mortality of 39.8%. Alcoholic liver disease is a significant cause of morbidity and mortality in New Mexico (USA), and we report here the clinical course and characteristics of three cases of patients with alcoholic cirrhosis who were admitted to our hospital with COVID-19.
2019年新型冠状病毒（COVID-19）于2019年12月由世界卫生组织报告，自那时起已演变成一场全球大流行，导致大量发病和死亡。高达50%的感染患者出现COVID-19的胃肠道症状和肝酶升高。最近的报告显示，已有肝病的COVID-19患者死亡率很高，相关死亡率为39.8%。酒精性肝病是美国新墨西哥州发病和死亡的一个重要原因，我们在此报告3例酒精性肝硬化患者因COVID-19入住我院的临床病程和特征。
